BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary - Trial NCT06304922
Access comprehensive clinical trial information for NCT06304922 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer
Observational
behavioral
Sponsor & Location
Assiut University
Timeline & Enrollment
N/A
Apr 01, 2024
Apr 01, 2026
Primary Outcome
Objective response rate.,Progression free survival
Summary
The main objective of this prospective study is to assess the clinical outcomes of platinum
 based chemotherapy cases either cisplatin or carboplatin according to BRCA status in
 neoadjuvant and recurrent ovarian cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06304922
Non-Device Trial